Sanuwave Health's (SNWV) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Sanuwave Health (NASDAQ: SNWV) has had its "sell (D-)" rating reaffirmed by Weiss Ratings, indicating a continuing negative view from analysts.
• Multiple research firms have shown varied opinions on Sanuwave Health, with Northland Securities rating it "outperform" and setting a target price of $55.00, while Roth Capital assigned a "buy" rating with a $53.00 price target.
• The company's recent financial performance showed a notable earnings beat, reporting $0.01 EPS against an expectation of ($0.09), with revenues slightly exceeding forecasts at $10.16 million.

Sanuwave Health (NASDAQ:SNWV - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other research firms have also commented on SNWV. Northland Securities started coverage on Sanuwave Health in a research report on Wednesday, September 3rd. They issued an "outperform" rating and a $55.00 price objective on the stock. Roth Capital set a $53.00 target price on Sanuwave Health and gave the company a "buy" rating in a research note on Tuesday. Northland Capmk upgraded Sanuwave Health to a "strong-buy" rating in a research note on Wednesday, September 3rd. Finally, Wall Street Zen upgraded Sanuwave Health from a "hold" rating to a "buy" rating in a research note on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $54.00.

Sanuwave Health Price Performance

NASDAQ:SNWV opened at $31.33 on Wednesday. The business's 50-day moving average is $37.69 and its two-hundred day moving average is $33.86. Sanuwave Health has a 12 month low of $5.63 and a 12 month high of $46.58. The firm has a market capitalization of $268.44 million, a PE ratio of -3.80 and a beta of 1.33.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.10. The company had revenue of $10.16 million during the quarter, compared to analysts' expectations of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Hedge Funds Weigh In On Sanuwave Health

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in Sanuwave Health in the second quarter worth about $26,000. BNP Paribas Financial Markets acquired a new position in Sanuwave Health in the second quarter worth about $46,000. Strategic Investment Solutions Inc. IL acquired a new position in Sanuwave Health in the first quarter worth about $47,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Sanuwave Health in the second quarter valued at approximately $52,000. Finally, New York State Common Retirement Fund acquired a new position in Sanuwave Health in the second quarter valued at approximately $102,000. 42.53% of the stock is currently owned by institutional investors and hedge funds.

About Sanuwave Health

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.